KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

Quality-of-life outcomes with pimitespib in patients with advanced gastrointestinal stromal tumor: results from the randomized, double-blind, placebo-controlled, phase III, CHAPTER-GIST-301 study.

Y Komatsu, N Taira, Y Kurokawa, Y Honma, A Sawaki, Y Naito, S Iwagami, T Takahashi, Y Hirano, Y Tanaka, T Nishida, T Doi

ESMO Open 11(3) 106088

PMID41785671
PMCIDPMC12972982
DOI10.1016/j.esmoop.2026.106088
发表日期2026-03-05
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

BACKGROUND: Health-related quality of life (HRQoL) has emerged as an important outcome following the introduction of tyrosine kinase inhibitors for metastatic gastrointestinal stromal tumors (GISTs). We report the HRQoL results from the randomized, placebo-controlled, phase III CHAPTER-GIST-301 study evaluating pimitespib as fourth-line therapy for metastatic GIST. PATIENTS AND METHODS: HRQoL was assessed using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 items (EORTC QLQ-C30) v3.0 and EuroQol Five Dimensions Questionnaire-5L (EQ-5D-5L) at baseline and scheduled study visits during the blinded period. Between-group change from baseline scores were compared using a mixed model repeated measure model. The percentage of patients with a clinically meaningful deterioration (≥10 point change from baseline) in HRQoL was calculated for each EORTC QLQ-C30 item. Time to deterioration (TTD) was calculated using the Kaplan-Meier method. RESULTS: Overall, 86 patients were randomized to receive pimitespib (n = 58) or placebo (n = 28) in the CHAPTER-GIST-301 study. Compliance across all HRQoL questionnaires exceeded 80% by week 18. Least-squares mean changes from baseline were generally similar between pimitespib and placebo treatment groups, with the exception of diarrhea and appetite loss. Items associated with a ≥10 point difference in EORTC QLQ-C30 were diarrhea (hazard ratio 4.82, 95% confidence interval 2.17-10.71), with almost no difference in other items. CONCLUSION: Pimitespib as a new treatment option in the fourth-line setting did not negatively impact HRQoL overall, with the exception of diarrhea and appetite loss, in patients with metastatic GIST.

KM 提取结果

1 个 Figure · 1 个 KM 面板

进入结果中心
KM Figure1 个面板

Figure 2

Figure 2 Kaplan–Meier curves of TTD . (EORTC QLQ-C30, CMD of ≥10 points) in (A) global health status, (B) physical functioning, (C) role functioning, (D) appetite loss, (E) diarrhea. CMD, clinically meaningful deterioration; EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 items; TTD, time to deterioration.

E

diarrhea

Figure 2 · Panel E

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel E 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似图例或人工水平线:轨迹出现不合理的共同平台疑似图例或人工水平线:轨迹出现不合理的共同平台曲线 1:extreme upward reversal
查看结果
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1 Least-squares mean change from baseline (standard deviation) in EORTC QLQ-C30 . (A) global health status, (B) physical functioning, (C) role functioning, (D) appetite loss, (E) diarrhea, and (F) EQ-VAS score. EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 items; EQ-VAS, EuroQol visual analogue scale; LS, least-squares; SE, standard error.
非 KM Figure
Figure 3Figure 3 Forest plot of time to deterioration (EORTC QLQ-C30, CMD of ≥10 points). CI, confidence interval; CMD, clinically meaningful deterioration; EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 items; HR, hazard ratio; NC, not calculable; NR, not reached; TTD, time to deterioration.
非 KM Figure